EUVIMEDEUVIMED entdecken
Systematische Übersicht

Cannabinoids for Substance Use Disorder Treatment: What Does the Current Evidence Say?

João Ariel Bonar Fernandes iD, Renato Filev, Thiago M Fidalgo

Cannabis & Cannabinoid Research · 01.10.2023 · 8 (5) · 703-715

DOI: 10.1089/can.2023.0065 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cannabis & Cannabinoid Research, online erschienen am 09.10.2023. Verfasst von João Ariel Bonar Fernandes und 2 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Psiquiatria, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Cannabinoids, Substance-Related Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 93 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prevalence of Substance Use Disorder (SUD) is increasing along with the need to develop approaches to reduce the harm associated with substance use, including investigating alternatives such as cannabinoids, which show promising results, although the current evidence is limited. This scoping review focuses on the limitations and potentials of cannabinoid-based treatments for SUDs.

Methods

We examined between-subject randomized controlled trials (RCTs) investigating the use of CBD and THC as pharmacological treatment for SUDs in adults, with the procedures attending the expectations of the Preferred Reporting Items for Scoping reviews and Meta-Analyses (PRISMA) for Scoping Reviews guidelines and assessed risk of bias using the Cochrane Risk of Bias Assessment Tool 2.

Results

Ten RCTs were included, with six demonstrating low risk of bias, and positive results were found for treating Cannabis Use Disorder, while contradictory results were found for Opioid Use Disorder, and inconclusive results for treating Cocaine Use Disorder.

Conclusions

CBD and THC demonstrate potential for treating some SUDs, but evidence is limited. Robust RCTs with larger samples and longer follow-up periods are necessary to assess carefully developed outcomes for different SUD patients. New cannabinoid-based medications and scientific-based policies may advance SUD treatment. A comprehensive approach to treatment and careful methodological choices may benefit patients with SUD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabinoidsSubstance-Related DisordersAdultHumans

Stichwörter der Autor:innen

cannabidiolcannabis use disordercocaine use disorderopioid use disordersubstance use disordertetrahydrocannabinol

Substanzen

Cannabinoids

Autor:innen und Institutionen

  • Departamento de Psiquiatria, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.

ORCID-Profile: João Ariel Bonar Fernandes

Zitieren

APA

Fernandes, J. A. B., Filev, R., & Fidalgo, T. M. (2023). Cannabinoids for Substance Use Disorder Treatment: What Does the Current Evidence Say?. Cannabis & Cannabinoid Research, 8(5), 703-715. https://doi.org/10.1089/can.2023.0065

Vancouver

Fernandes JAB, Filev R, Fidalgo TM. Cannabinoids for Substance Use Disorder Treatment: What Does the Current Evidence Say?. Cannabis & Cannabinoid Research. 2023;8(5):703-715. doi:10.1089/can.2023.0065

BibTeX
@article{Fernandes2023,
  author = {Fernandes, João Ariel Bonar and Filev, Renato and Fidalgo, Thiago M},
  title = {Cannabinoids for Substance Use Disorder Treatment: What Does the Current Evidence Say?},
  journal = {Cannabis & Cannabinoid Research},
  year = {2023},
  volume = {8},
  number = {5},
  pages = {703--715},
  doi = {10.1089/can.2023.0065}
}
Kostenlos starten →